PATIENT WEBSITE

FOR us HEALTHCARE professionals only



Dolphin image for AKYNZEO

Efficacy in preventing CINV in cisplatin-treated patients

SEE THE DATA

One dose* for 5 days of CINV prevention

SEE DOSING

AKYNZEO® provides superior CINV prevention

Complete response following AC chemotherapy

COMPLETE RESPONSE (NO EMESIS AND NO USE OF RESCUE MEDICATION) FOR 5 DAYS IN AC-TREATED PATIENTS, CYCLE 11

AKYNZEO
(n=724)
Palonosetron 0.5 mg
(n=725)
P value
from Cochran-Mantel-Haenszel test, stratified by age class and region
Primary endpoint:
Complete response, delayed phase (25 to 120 hours after AC regimen) 77% 70% P=.001
Major secondary endpoints:
Complete response, acute phase (0 to 24 hours after AC regimen) 88% 85% P=.047
Complete response, overall phase (0 to 120 hours after AC regimen) 74% 67% P=.001

See safety profile in AC-treated patients.

Sustained efficacy across multiple cycles in AC-treated patients

COMPLETE RESPONSE IN DELAYED CINV IN CYCLES 2-6 IN AC-TREATED PATIENTS1,2†

AKYNZEO complete response in Cycles 2-6

Complete response in the delayed phase was higher with AKYNZEO among patients receiving AC chemotherapy treatment during all cycles (Cycles 2-6)1

After completion of Cycle 1, patients had the option to participate in a multiple-cycle extension, receiving the same treatment as assigned in Cycle 1.1
  • 88.4% of patients continued treatment in the multiple-cycle extension1
  • 62.3% of patients completed the multiple-cycle extension up to a maximum of 8 treatment cycles1

AKYNZEO study design in patients receiving AC chemotherapy treatment1

Phase 3, multinational, multicenter, randomized, double-blind, double-dummy, parallel-group study evaluating AKYNZEO (n=724) vs oral palonosetron (n=725) in AC-based chemotherapy, which was considered MEC at the time the study was conducted1,3:

  • 97% of patients were undergoing chemotherapy for breast cancer3
  • Day 1: AKYNZEO + dexamethasone 12 mg vs palonosetron 0.5 mg + dexamethasone 20 mg1
  • Days 2-3: No antiemetic treatment1

Efficacy in preventing CINV in cisplatin-treated patients

SEE THE DATA

One dose* for 5 days of CINV prevention

SEE DOSING
References: 1. AKYNZEO® (netupitant/palonosetron) capsules Full Prescribing Information. 2. Data on file. Helsinn Healthcare SA, Lugano, Switzerland. 3. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328-1333.